Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
Gilead will present results from more than 50 studies, including late-breaking data and two oral presentations, at HIV Glasgow 2026 taking place November 8-11. Highlights include Phase 2 PURPOSE 5 persistence data for twice-yearly lenacapavir PrEP, Phase 3 ARTISTRY data for the once-daily BIC/LEN regimen (approved as Bixlenvo in the U.S. in August 2026), and Phase 3 ISLEND results for a once-weekly oral islatravir/lenacapavir regimen developed with Merck.
Key figures
- Drug Name
- lenacapavir (Yeytuo/Yeztugo/Sunlenca); BIC/LEN (Bixlenvo); ISL/LEN; GS-3242; amtabafusp alfa (GS-8588)
- Conference dates
- November 8-11, 2026
- Studies presented
- 50
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.